eISSN: 2299-0054
ISSN: 1895-4588
Videosurgery and Other Miniinvasive Techniques
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

4/2014
vol. 9
 
Share:
Send email
Share:
abstract:
Original paper

Robotic stereotactic body radiation therapy for liver-limited malignant tumors

Mariusz Frączek
,
Jacek Sobocki
,
Katarzyna Pędziwiatr
,
Edward Skrocki
,
Norbert Piotrkowicz
,
Dobromira Tyc-Szczepaniak
,
Elżbieta Korab-Chrzanowska
,
Piotr Hevelke
,
Maciej Krasnodębski
,
Waldemar Koszewski

Videosurgery Miniinv 2014; 9 (4): 511–516
DOI: https://doi.org/10.5114/wiitm.2014.44258
Online publish date: 2014/07/23
View full text Get citation
 
PlumX metrics:
Introduction: Stereotactic body radiotherapy (SBRT) is rapidly gaining favor as a new treatment modality for malignant liver tumors. Most of the studies have recruited patients with disseminated disease originating from the liver. This study focuses on disease limited to the liver.

Aim: To perform a retrospective analysis of all patients with liver tumors treated by robotic stereotactic body radiation therapy in a single center.

Material and methods: The study included 13 patients with 22 lesions. The inclusion criteria were: patients with 1–4 inoperable liver lesions and absence of any extrahepatic disease. All but 3 patients received 3 fractions delivered by the Cyberknife system of a total of 45 grey (Gy). The other 3 patients received 30 Gy.

Results: The median follow-up time was 10.8 months (range: 7–16). The median dose was 41.5 Gy (range: 30–45). One lesion regressed (8%). In 5 patients, the disease was locally stabilized (38%), and in 7 other patients progression occurred (54%). Twelve patients (92%) are still alive, and 1 patient (8%) died. In 1 patient a new cancer (leukemia) was diagnosed.

Conclusions: The SBRT is well tolerated and effective for local control of most liver malignant tumors. It appears that SBRT is best suited for those patients in whom systemic recurrence can be controlled by chemotherapy. Further studies are mandatory to elucidate these effects on tumors of varying histology and to elaborate upon criteria used to select patients who can benefit most from this treatment.
keywords:

cyberknife, liver tumors, stereotactic body radiotherapy
  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.